{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:34:15Z","timestamp":1791844455385,"version":"4.3.4"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.schres.2021.01.021","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T09:03:51Z","timestamp":1613552631000},"page":"3-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"229","author":[{"given":"Giulia","family":"Paris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bighelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Deste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schneider-Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.schres.2021.01.021_bb0005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-006-0541-x","article-title":"Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol","volume":"188","author":"Andrezina","year":"2006","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.schres.2021.01.021_bb0010","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2165\/00003495-200565090-00003","article-title":"Pharmacological management of acute agitation","volume":"65","author":"Battaglia","year":"2005","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.schres.2021.01.021_bb0015","first-page":"120","article-title":"Improving the quality of randomized controlled trials in Chinese herbal medicine, part I: clinical trial design and methodology","volume":"4","author":"Bian","year":"2006","journal-title":"Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine"},{"issue":"1","key":"10.1016\/j.schres.2021.01.021_bb0020","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1186\/s12888-018-1964-8","article-title":"Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis","volume":"18","author":"Bighelli","year":"2018","journal-title":"BMC psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2021.01.021_bb0025","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.59.5.441","article-title":"A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia","volume":"59","author":"Breier","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2021.01.021_bb0030","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4088\/JCP.v61n1208","article-title":"Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group","volume":"61","author":"Brook","year":"2000","journal-title":"The Journal of clinical psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2021.01.021_bb0035","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.4088\/JCP.v68n1207","article-title":"Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety","volume":"68","author":"Citrome","year":"2007","journal-title":"The Journal of clinical psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2021.01.021_bb0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0196-0644(87)80179-8","article-title":"Haloperidol for sedation of disruptive emergency patients","volume":"16","author":"Clinton","year":"1987","journal-title":"Ann. Emerg. Med."},{"issue":"2","key":"10.1016\/j.schres.2021.01.021_bb0045","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s002130000658","article-title":"Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial","volume":"155","author":"Daniel","year":"2001","journal-title":"Psychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.schres.2021.01.021_bb0050","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0165-0327(99)00010-5","article-title":"Psychomotor agitation: poorly defined and badly measured","volume":"55","author":"Day","year":"1999","journal-title":"J. Affect. Disord."},{"issue":"7\u20138","key":"10.1016\/j.schres.2021.01.021_bb0055","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat. Med."},{"key":"10.1016\/j.schres.2021.01.021_bb0060","author":"FDA"},{"key":"10.1016\/j.schres.2021.01.021_bb0065","author":"FDA"},{"key":"10.1016\/j.schres.2021.01.021_bb0070","author":"FDA"},{"issue":"1","key":"10.1016\/j.schres.2021.01.021_bb0075","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/YCO.0b013e3282f31137","article-title":"Personality disorders and violence","volume":"21","author":"Fountoulakis","year":"2008","journal-title":"Current opinion in psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2021.01.021_bb0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00004850-200501000-00010","article-title":"Imputing response rates from means and standard deviations in meta-analyses","volume":"20","author":"Furukawa","year":"2005","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.schres.2021.01.021_bb0085","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010919","article-title":"Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis","volume":"6","author":"Furukawa","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.schres.2021.01.021_bb0090","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"issue":"2","key":"10.1016\/j.schres.2021.01.021_bb0095","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res. Synth. Methods"},{"key":"10.1016\/j.schres.2021.01.021_bb0100","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-244X-2-11","article-title":"TREC-Rio trial: a randomised controlled trial for rapid tranquillisation for agitated patients in emergency psychiatric rooms ISRCTN44153243","volume":"2","author":"Huf","year":"2002","journal-title":"BMC psychiatry"},{"issue":"10202","key":"10.1016\/j.schres.2021.01.021_bb0105","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.schres.2021.01.021_bb0110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"2","key":"10.1016\/j.schres.2021.01.021_bb0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2006-931541","article-title":"What would the patient choose? Subjective comparison of atypical and typical neuroleptics","volume":"39","author":"Karow","year":"2006","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.schres.2021.01.021_bb0120","first-page":"230","article-title":"A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation","volume":"13","author":"Katagiri","year":"2013","journal-title":"BMC psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2021.01.021_bb0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2016.07.017","article-title":"Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: a pragmatic double-blind randomized trial","volume":"176","author":"Kittipeerachon","year":"2016","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2021.01.021_bb0130","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4088\/JCP.v62n0104","article-title":"Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients","volume":"62","author":"Lesem","year":"2001","journal-title":"The Journal of clinical psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2021.01.021_bb0135","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/sj.npp.1300873","article-title":"The relative sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in antipsychotic drug trials","volume":"31","author":"Leucht","year":"2006","journal-title":"Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology"},{"issue":"9657","key":"10.1016\/j.schres.2021.01.021_bb0140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.schres.2021.01.021_bb0145","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"AJP"},{"issue":"2","key":"10.1016\/j.schres.2021.01.021_bb0150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1017\/S1461145710001380","article-title":"Evidence-based pharmacotherapy of schizophrenia","volume":"14","author":"Leucht","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.schres.2021.01.021_bb0155","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.euroneuro.2011.11.007","article-title":"Equipercentile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area","volume":"22","author":"Leucht","year":"2012","journal-title":"European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.schres.2021.01.021_bb0160","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.schres.2007.09.006","article-title":"Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI","volume":"98","author":"Levine","year":"2008","journal-title":"Schizophr. Res."},{"issue":"7","key":"10.1016\/j.schres.2021.01.021_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.schres.2021.01.021_bb0170","author":"National Institute for Clinical Excellence"},{"issue":"4","key":"10.1016\/j.schres.2021.01.021_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med."},{"key":"10.1016\/j.schres.2021.01.021_bb0180","article-title":"Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)","volume":"7","author":"Ostinelli","year":"2017","journal-title":"The Cochrane database of systematic reviews"},{"key":"10.1016\/j.schres.2021.01.021_bb0185","article-title":"Aripiprazole (intramuscular) for psychosis-induced aggression or agitation (rapid tranquillisation)","volume":"1","author":"Ostinelli","year":"2018","journal-title":"The Cochrane database of systematic reviews"},{"issue":"10039","key":"10.1016\/j.schres.2021.01.021_bb0190","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0140-6736(15)01121-6","article-title":"Schizophrenia","volume":"388","author":"Owen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2021.01.021_bb0195","doi-asserted-by":"crossref","first-page":"j2970","DOI":"10.1136\/bmj.j2970","article-title":"China vows to clamp down on academic fraud amid medical journal scandal","volume":"357","author":"Parry","year":"2017","journal-title":"BMJ (Clinical research Ed.)"},{"key":"10.1016\/j.schres.2021.01.021_bb0200","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2017"},{"issue":"7625","key":"10.1016\/j.schres.2021.01.021_bb0205","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/bmj.39341.608519.BE","article-title":"Rapid tranquillisation in psychiatric emergency settings in India: pragmatic randomised controlled trial of intramuscular olanzapine versus intramuscular haloperidol plus promethazine","volume":"335","author":"Raveendran","year":"2007","journal-title":"BMJ (Clinical research Ed.)"},{"issue":"3","key":"10.1016\/j.schres.2021.01.021_bb0210","first-page":"112","article-title":"Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia","volume":"35","author":"Reschke","year":"1974","journal-title":"Diseases of the nervous system"},{"key":"10.1016\/j.schres.2021.01.021_bb0215","first-page":"1","article-title":"Psychomotor agitation in psychiatry: an Italian expert consensus","volume":"3","author":"Sacchetti","year":"2017","journal-title":"Evidence-based Psychiatric Care"},{"issue":"1\u20133","key":"10.1016\/j.schres.2021.01.021_bb0220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.schres.2013.10.029","article-title":"Imputation of response rates from means and standard deviations in schizophrenia","volume":"151","author":"Samara","year":"2013","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2021.01.021_bb0225","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12874-018-0554-2","article-title":"Quality of randomized controlled trials of new generation antidepressants and antipsychotics identified in the China National Knowledge Infrastructure (CNKI): a literature and telephone interview study","volume":"18","author":"Tong","year":"2018","journal-title":"BMC Med. Res. Methodol."},{"issue":"11","key":"10.1016\/j.schres.2021.01.021_bb0230","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jclinepi.2004.02.018","article-title":"Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time","volume":"57","author":"Trikalinos","year":"2004","journal-title":"J. Clin. Epidemiol."},{"issue":"3","key":"10.1016\/j.schres.2021.01.021_bb0235","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ije\/dys041","article-title":"Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews","volume":"41","author":"Turner","year":"2012","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.schres.2021.01.021_bb0240","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1192\/bjp.180.6.490","article-title":"Violence and schizophrenia: examining the evidence","volume":"180","author":"Walsh","year":"2002","journal-title":"The British journal of psychiatry: the journal of mental science"},{"issue":"1","key":"10.1016\/j.schres.2021.01.021_bb0245","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5811\/westjem.2011.9.6866","article-title":"The psychopharmacology of agitation: consensus statement of the american association for emergency psychiatry project Beta psychopharmacology workgroup","volume":"13","author":"Wilson","year":"2012","journal-title":"West. J. Emerg. Med."},{"key":"10.1016\/j.schres.2021.01.021_bb0250","first-page":"i5396","article-title":"80% of China\u2019s clinical trial data are fraudulent, investigation finds","volume":"355","author":"Woodhead","year":"2016","journal-title":"BMJ (Clinical research Ed.)"},{"key":"10.1016\/j.schres.2021.01.021_bb0255","author":"World Health Organization"},{"issue":"7","key":"10.1016\/j.schres.2021.01.021_bb0260","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/appi.ajp.158.7.1149","article-title":"Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia","volume":"158","author":"Wright","year":"2001","journal-title":"AJP"},{"key":"10.1016\/j.schres.2021.01.021_bb0265","series-title":"Abstracts of the 14th Cochrane Colloquium, 2006 23\u201326 Oct, Dublin, UK","article-title":"Investigation of authenticity of \u2018claimed\u2019 randomized controlled trials (RCTs) and quality assessment of RCT reports published in China. Come to the craic","author":"Wu","year":"2006"},{"key":"10.1016\/j.schres.2021.01.021_bb0270","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1745-6215-10-46","article-title":"Randomized trials published in some Chinese journals: how many are randomized?","volume":"10","author":"Wu","year":"2009","journal-title":"Trials"},{"issue":"3","key":"10.1016\/j.schres.2021.01.021_bb0275","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.clinthera.2010.03.006","article-title":"Systematic reviews of assessment measures and pharmacologic treatments for agitation","volume":"32","author":"Zeller","year":"2010","journal-title":"Clin. Ther."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421000633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996421000633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:39:48Z","timestamp":1760297988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996421000633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":55,"alternative-id":["S0920996421000633"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2021.01.021","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2021.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}